Jyothy Labs Q2 PAT seen up 26% YoY to Rs. 53.1 cr: Motilal Oswal

Net Sales are expected to increase by 10 percent Y-o-Y (up 8.6 percent Q-o-Q) to Rs. 636.1 crore, according to Motilal Oswal.

Jyothy Labs Q4 PAT may dip 25.8% YoY to Rs 37.4 cr: Motilal Oswal

Net Sales are expected to increase by 7.8 percent Y-o-Y (down 0.6 percent Q-o-Q) to Rs 525.5 crore, according to Motilal Oswal.

Jyothy Labs Q2 PAT may dip 13.8% YoY to Rs 52.3 cr: Motilal Oswal

Net Sales are expected to increase by 11 percent Y-o-Y (up 6.3 percent Q-o-Q) to Rs 554.6 crore, according to Motilal Oswal.

Jyothy Labs Q1 PAT may dip 4.2% YoY to Rs. 48 cr: Arihant Capital

Net Sales are expected to increase by 9.5 percent Y-o-Y (down 4.3 percent Q-o-Q) to Rs. 474 crore, according to Arihant Capital.

Jyothy Labs Q4 PAT seen up 36.5% YoY to Rs 35.5 cr: Sharekhan

Net Sales are expected to increase by 26.3 percent Y-o-Y (up 2.9 percent Q-o-Q) to Rs 482.9 crore, according to Sharekhan.

Jyothy Laboratories Q2 PAT may dip 0.1% YoY to Rs. 45.3 cr: Kotak

Net Sales are expected to increase by 6.5 percent Y-o-Y (up 10.7 percent Q-o-Q) to Rs. 455.5 crore, according to Kotak.

Jyothy Laboratories Q1 PAT seen up 25.1% YoY to Rs. 40.5 cr: ICICI Direct

Net Sales are expected to increase by 7.1 percent Y-o-Y (down 14.5 percent Q-o-Q) to Rs. 431.2 crore, according to ICICI Direct.

Jyothy Laboratories sees soft Q4; valuation discount to peers merits attention

Jyothy Laboratories Q4 PAT may dip 7.4% YoY to Rs. 55.9 cr: ICICI Direct

Net Sales are expected to increase by 9.7 percent Y-o-Y (up 20.5 percent Q-o-Q) to Rs. 523.5 crore, according to ICICI Direct.

Jyothy Laboratories (Standalone) Q4 PAT may dip 0.4% YoY to Rs. 60.1 cr: Kotak

Net Sales are expected to increase by 6.4 percent Y-o-Y (up 16.9 percent Q-o-Q) to Rs. 507.6 crore, according to Kotak.

Godrej Consumer Products: International business remains a drag; stay on the sidelines

Jyothy Laboratories (Standalone) Q3 PAT seen up 18.1% YoY to Rs. 44 cr: Kotak

Net Sales are expected to increase by 10 percent Y-o-Y (up 7.6 percent Q-o-Q) to Rs. 460.2 crore, according to Kotak.

Jyothy Laboratories Q2 PAT may dip 4.3% YoY to Rs. 40.5 cr: ICICI Direct

Net Sales are expected to increase by 7.4 percent Y-o-Y to Rs. 450.5 crore, according to ICICI Direct.

Jyothy Laboratories Q1 PAT seen up 141.6% YoY to Rs. 49.8 cr: ICICI Direct

Net Sales are expected to increase by 26.3 percent Y-o-Y (down 10.9 percent Q-o-Q) to Rs. 450.4 crore, according to ICICI Direct.

Jyothy Laboratories Q4 PAT may dip 63.3% YoY to Rs. 40.3 cr: ICICI Direct

Net Sales are expected to increase by 12.9 percent Y-o-Y (up 22.4 percent Q-o-Q) to Rs. 511 crore, according to ICICI Direct.

Expect margin to sustain between 15-16% for next few quarters: Jyothy Labs

Jyothy Laboratories reported a good quarter. Margins have beat estimates while EBITDA grew almost 37 percent, in fact, margins have improved despite lower gross margins and higher ad spends. In an interview to CNBC-TV18, Ullas Kamath, Joint MD of the company discussed the Q3 performance.

Will clarify on Henkel deal by October 31: Jyothy Laboratories

Jyothy Laboratories reported a weak set of Q1 earnings. K Ullas Kamath, Joint MD and CFO of the company spoke about the results and his outlook for the company.

See demand uptick after initial cash ban shocker: Jyothy Labs

In an interview with CNBC-TV18, K Ullas Kamath, Joint MD and CFO of the company said that due to demonetisation sales in November saw a decline of 19 percent but it grew 14 percent in December and a similar trend is being seen for the month of January as well.

Jyothy Lab Q1 PAT seen up 33.5% to Rs 59.5 cr: Axis Securities

Net Sales are expected to up 12.1 percent Y-o-Y to Rs 464.0 crore, according to Axis Securities

Jyothy Labs Q3 profit seen up 38% led by Maxo, EBITDA growth

Revenue is likely to increase 5.9 percent to Rs 360.5 crore in Q3 compared to Rs 380 crore in same quarter last year.

Ujala has no competiton; saw good growth in Q2: Jyothy Labs

In an interview to CNBC-TV18, K Ullas Kamath, Joint MD & CFO of Jyothy Laboratories spoke about their second quarter numbers.

Jyothy Labs Q2 profit seen up 19%, margin may rise

Analysts polled by CNBC-TV18 expect Ujala to see better quarter owing to low base and Henko may face see stiff competition from peers post price cut. Soap segment is likely to see better profitability while detergents may see slowdown and revenues may be weak owing to price cuts.

Jyothy Labs Q4 profit seen up 29% to Rs 27.6 cr: Poll

Jyothy Laboratories's fourth quarter consolidated profit after tax is expected to increase 28.6 percent year-on-year to Rs 27.6 crore, according to a CNBC-TV18 poll.

See H2 13-14% EBITDA margin; 20% FY15 profit growth: Jyothy

K Ullas Kamath, joint managing director and CFO of Jyothy Laboratories says the company will get the benefit of softer raw material costs in the third and fourth quarter. The company‘s expenditure rose to 12.6 percent this quarter, higher than the usual 10 percent, he adds.

Hope to maintain 15% EBITDA margin going ahead: Jyothy Labs

FMCG player Jyothy Labs reported a 63.11 percent increase in its standalone net profit to Rs 27.37 crore for the third quarter ended December 31, 2013.